ArticleFrontiers in oncology2026
Achieving "textbook outcome" after hepatectomy for hepatocellular carcinoma in the era of enhanced recovery: development and validation of a clinical nomogram.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traditional perioperative metrics such as complication rates and length of stay (LOS) are fragmented and fail to capture the "ideal" recovery trajectory. "Textbook outcome" (TO) has emerged as a composite quality metric representing optimal surgical results. However, validated tools for predicting TO specifically for patients with hepatocellular carcinoma (HCC) undergoing hepatectomy within an Enhanced Recovery After Surgery (ERAS) pathway remain scarce, particularly models integrating the albumin-bilirubin (ALBI) grade. Methods: We conducted a single-center retrospective analysis of 685 consecutive patients who underwent curative hepatectomy for HCC between January 2021 and December 2025. TO was defined as the concurrent fulfillment of six criteria: no Clavien-Dindo grade ≥III complications, no prolonged LOS (>75th percentile), no readmission within 30 days, no 90-day mortality, R0 resection, and no clinically relevant bile leak. The cohort was randomly divided into a training set ( Results: The overall TO rate was 62.8% (430/685). In the training cohort, the multivariable analysis identified ALBI grade (OR = 0.45, 95%CI = 0.28-0.71), minimally invasive surgery (MIS) approach (OR = 2.15, 95%CI = 1.45-3.20), tumor size <5 cm (OR = 1.88, 95%CI = 1.22-2.90), and absence of microvascular invasion (OR = 1.65, 95%CI = 1.10-2.48) as independent predictors of achieving TO. The nomogram demonstrated good discrimination, with Conclusion: TO serves as a comprehensive standard for patient-centered care. Our preliminary nomogram, which incorporates the objective ALBI grade and the surgical approach, offers a practical tool to predict ideal recovery likelihood. However, external validation is required before widespread clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.